

This article was downloaded by:

On: 23 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713617200>

THE SYNTHESIS OF C-9 MODIFIED DERIVATIVES OF THE α -METHYL GLYCOSIDE OF KDN METHYL ESTER

Adele K. Norton^a; Gaik B. Kok^a; Mark von Itzstein^b

^a Department of Medicinal Chemistry, Monash University, Victoria, Australia ^b Griffith University (Gold Coast Campus), Queensland, Australia

Online publication date: 31 March 2001

To cite this Article Norton, Adele K. , Kok, Gaik B. and von Itzstein, Mark(2001) 'THE SYNTHESIS OF C-9 MODIFIED DERIVATIVES OF THE α -METHYL GLYCOSIDE OF KDN METHYL ESTER', *Journal of Carbohydrate Chemistry*, 20: 2, 227 – 238

To link to this Article: DOI: 10.1081/CAR-100103960

URL: <http://dx.doi.org/10.1081/CAR-100103960>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

THE SYNTHESIS OF C-9 MODIFIED DERIVATIVES OF THE α -METHYL GLYCOSIDE OF KDN METHYL ESTER

Adele K. Norton,¹ Gaik B. Kok,¹ and Mark von Itzstein^{1,2,*}

¹Department of Medicinal Chemistry, Monash University,
381 Royal Parade, Parkville 3052, Victoria, Australia

²Centre for Biomolecular Science and Drug Discovery,
Griffith University (Gold Coast Campus),
50 Gold Coast Mail Centre, Queensland 9726, Australia

ABSTRACT

The synthesis of a range of C-9 substituted derivatives of the α -methyl glycoside of KDN methyl ester (2) is reported. 9-Deoxy-9-iodo, 9-deoxy-9-thioacetyl and 9-azido-9-deoxy derivatives (compounds 10, 12 and 13) were all prepared from the corresponding 9-*O*-tosylate 8. Catalytic hydrogenation of 10 and 13 results in reduction to give the 9-deoxy and 9-amino-9-deoxy derivatives 20 and 15, respectively. Further derivatisation of the amine 15 into compounds 17 and 18 was achieved via standard acylation procedures.

INTRODUCTION

Sialic acids are a family of more than 40 different sugars which have a 3-deoxy-2-nonulosonic acid structure.¹ The most commonly occurring sialic acids are *N*-acetylneuraminic acid (Neu5Ac) and *N*-glycolylneuraminic acid (Neu5Gc) with structural diversity arising from substitutions (e.g., *O*-acetylation, *O*-methylation and *O*-sulfonylation) of the various hydroxyl groups of these systems. As terminal

*Corresponding author. E-mail: m.vonitzstein@mailbox.gu.edu.au

carbohydrate units of many glycoproteins and glycolipids, sialic acids take part in a myriad of biological functions including molecular recognition, cell adhesion and inflammation.¹ In 1986, 3-deoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid (KDN, **1**), a unique C-5 deaminated member of the sialic acid family, was discovered from the membrane polysialoglycoproteins (PSGP) of *Salmo gaidneri* (rainbow trout) eggs.² Studies have since shown that only sialic acid residues with an acylamino group at C-5 are cleaved by bacterial sialidases.³ Therefore, it is likely that as a terminal unit of the PSGP chains, KDN protects the membrane from bacterial degradation. Subsequently, the natural presence of KDN has been reported for a wide variety of organisms ranging from bacteria and lower vertebrates to higher vertebrates including mammals,⁴⁻⁶ suggesting its wide occurrence in nature.

Recently, Li and coworkers reported new sialidases that have unique roles in KDN metabolism. For example, the deaminoneuraminic acid residue-cleaving enzyme, KDNase, specifically hydrolyses the ketosidic linkages of KDN but not *N*-acylneuraminyl linkages and was first isolated from the liver of the loach (*Misgurnus fossilis*).⁷ The KDN-cleaving enzyme designated KDNase Sm has been induced and purified from *Sphingobacterium multivorum*.⁸ Moreover this protein has been shown⁹ to be a retaining enzyme not unlike the sialidases of bacterial and viral origin.

A large amount of work has been directed towards the synthesis of analogues and derivatives of naturally occurring sialic acids both for their use as probes for the study of sialic acid recognising proteins, and for investigating substrate specificities of the enzymes involved in sialic acid metabolism.^{10,11} Further study of the biological roles of KDN requires the synthesis of more complex analogues and derivatives of **1**. We report here the synthesis of some C-9 modified analogues of the α -methyl glycoside of KDN methyl ester **2** that may be useful as chemical probes to elucidate the sub-structural requirements for substrate/inhibitor recognition by the enzymes involved in KDN metabolism.

RESULTS AND DISCUSSION

As KDN-bearing glycoconjugates are α -linked, we have chosen the α -methyl glycoside of KDN methyl ester **2** as the key starting material for this study. The synthesis of this compound has previously been reported in the literature. Hence, treatment¹² of the methyl ester of KDN **3**, using Fischer's methyl glycosidation method under controlled conditions (70°C for 15 h), resulted in a mixture of both α and β -methyl glycosides (**2** and **4**) of which the latter was the major product (74%). The α -glycoside **2** was obtained in only 4% yield. Given that there is precedent in the literature for the stereoselective synthesis of the α -methyl glycoside of Neu5Ac methyl ester from the 2- β -chloride, methyl 5-acetamido-4,7,8,9-tetra-*O*-acetyl-2-chloro-2,3,5-trideoxy-D-glycero- β -D-galacto-2-nonulopyranosonate (**5**),¹³ we thought it reasonable to explore this methodology for the synthesis of **2**. Accordingly, exposure of the methyl ester of KDN **3** to acetyl chloride gave the 2- β -chloride, methyl 4,5,7,8,9-penta-*O*-acetyl-2-chloro-2,3-dideoxy-D-glycero- β -D-



galacto-2-nonulopyranosonate (**6**). Subsequent treatment of the 2- β -chloride (**6**) with methanol at room temperature for one hour led to the formation of **7** in good yield (87%, 2 steps). The α -methyl glycoside **2** was obtained as the only product following de-*O*-acetylation of **7** under standard Zemplen conditions. Both compounds **2** and **7** were found to be identical to known materials.¹²

The 9-deoxy-9-iodo, 9-azido-9-deoxy and 9-deoxy-thioacetyl derivatives of **2** can be accessed via nucleophilic displacement of a tosyl group. Selective tosylation¹⁴ and tritylation¹⁵ of *N*-acetylneuraminic acid derivatives has been previously reported. Selective tosylation at C-9 of the KDN derivative **2** was achieved in high yield (96%) by the reaction with *p*-toluenesulfonyl chloride initially at 0°C (2.5 h) and then at 5°C (20 h) to produce the 9-*O*-tosylate **8**, which was fully characterised as the peracetate **9**. Reaction of **8** with sodium iodide in acetone under reflux proceeded uneventfully to produce iodide **10** in high yield (96%). The appearance of a resonance at δ 15.9 ppm for C-9 in the ¹³C NMR spectrum is consistent with substitution of an iodo moiety at this position.¹⁶ The iodide **10** was further characterised as the peracetate **11**. Introduction of sulfur at C-9 via the reaction of **8** with potassium thioacetate in acetone proceeded with some concomitant de-*O*-acetylation, as was evident by TLC analysis of the crude reaction mixture. Therefore, for ease of workup, the crude reaction mixture was acetylated and then purified by chromatography which afforded the peracetate **12** in good yield (66%, 2 steps).


The introduction of a nitrogen functionality at C-9 via the azide was achieved by treatment of the 9-*O*-tosylate **8** with lithium azide in dimethylformamide at 50°C, resulting in the formation of the 9-azide **13** in high yield (91%). An attempt to synthesise this compound directly from the methyl ketoside of KDN methyl ester **2** using well-known Mitsunobu chemistry (TPP, DIAD, TMSN₃, DMF) also gave **13**, albeit in moderate yield (54%). This is in comparison to an overall yield of 87% for the two-step procedure via the 9-*O*-tosylate **8**. The 9-azide **13** was further characterised as the peracetate **14**.

The introduction of an azido moiety functionally allowed access to a range of other nitrogen-substituted compounds for structure-activity relationship studies. Hence, hydrogenation of the 9-azide **13** in the presence of 10% palladium on carbon in MeOH produced the 9-amine **15** in quantitative yield. This compound was fully characterised as the peracetate **16** that was then de-*O*-acetylated to produce the 9-acetamide **17** in good yield (72%). Acylation of the amine **15** with benzoyl chloride in the presence of triethylamine provided the 9-benzamido-9-deoxy compound **18** in 68% yield. This compound was further characterised as the peracetate **19**.

Finally, under hydrogenolysis conditions (50 psi H₂, 10% Pd/C), the 9-iodide **10** was converted into the corresponding 9-deoxy compound **20** in quantitative yield. Further characterisation of this compound involved converting it to the peracetate **21**.

In conclusion, we have synthesised a range of novel C-9 substituted derivatives of the methyl ketoside of KDN methyl ester. These systems should be useful as probes for the study of enzymes involved in KDN/sialic acid metabolism.





Compound	R ₁	R ₂	R ₃	R ₄	R ₅
1	COOH	OH	H	OH	OH
2	OMe	COOMe	H	OH	OH
3	COOMe	OH	H	OH	OH
4	COOMe	OMe	H	OH	OH
5	COOMe	Cl	Ac	NHAc	OAc
6	COOMe	Cl	Ac	OAc	OAc
7	OMe	COOMe	Ac	OAc	OAc
8	OMe	COOMe	H	OH	OTs
9	OMe	COOMe	Ac	OAc	OTs
10	OMe	COOMe	H	OH	I
11	OMe	COOMe	Ac	OAc	I
12	OMe	COOMe	Ac	OAc	SAc
13	OMe	COOMe	H	OH	N ₃
14	OMe	COOMe	Ac	OAc	N ₃
15	OMe	COOMe	H	OH	NH ₂
16	OMe	COOMe	Ac	OAc	NHAc
17	OMe	COOMe	H	OH	NHAc
18	OMe	COOMe	H	OH	NHBz
19	OMe	COOMe	Ac	OAc	NHBz
20	OMe	COOMe	H	OH	H
21	OMe	COOMe	Ac	OAc	H



EXPERIMENTAL

General Methods. ^1H NMR (300 MHz) and ^{13}C NMR (75 MHz) spectra (in δ ppm) were recorded on a Bruker AMX300 spectrometer and were referenced using solvent residues; J -values are in hertz (Hz). Both low resolution (LR) and high resolution (HR) fast atom bombardment (FAB) mass spectra were obtained using a JEOL JMS-DX 300 spectrometer. Optical rotations were measured using a JASCO DIP-370 polarimeter with a path length 50 mm; $[\alpha]_{\text{D}}$ -values are in units of $10^{-1} \text{ deg cm}^2 \text{ g}^{-1}$; concentrations are quoted in $10^{-2} \text{ deg cm}^{-3}$. IR spectra were recorded using a Hitachi 270-30 infrared spectrophotometer. Column chromatography was performed on Merck silica gel 60 (0.040–0.063 mm). Reactions were monitored by TLC on Kieselgel 60 F₂₅₄ plate (Merck 5554) and spots were detected under ultraviolet (UV) irradiation and by spraying with a 95% aq. ethanol solution containing 5% H₂SO₄ and charring at ca. 180°C. Microanalyses were performed by the Chemical and Microanalytical Service, Essendon, Victoria. KDN was prepared by aldolase (EC 4.1.3.3) condensation of D-mannose and pyruvate according to the literature.¹⁷ Methanolysis of **1** and treatment of the resulting methyl ester **3** with neat acetyl chloride (rt for 2.5 days) afforded the 2- β -chloride, methyl 4,5,7,8,9-penta-*O*-acetyl-2-chloro-2,3-dideoxy-D-glycero- β -D-galacto-2-nonulopyranosonate (**6**) (95%) which was used in subsequent step without further purification. Spectral data for 2- β -chloride (**6**) were consistent with the literature.¹⁸

General Procedure for Acetylation. Approximately 50–100 mg of the compound to be acetylated was dissolved in pyridine (1 mL) and the solution treated with Ac₂O (0.5 mL) and DMAP (ca. 5 mg) at rt for 16 h. The mixture was then concentrated to dryness and the residue chromatographed on silica using the solvent(s) specified.

Methyl (Methyl 3-Deoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (2). A solution of the crude 2- β -chloride, methyl 4,5,7,8,9-penta-*O*-acetyl-2-chloro-2,3-dideoxy-D-glycero- β -D-galacto-2-nonulopyranosonate (**6**) (7.14 g, 13.98 mmol) in anhydrous methanol was stirred at rt for 1 h. The reaction mixture was then concentrated under reduced pressure which gave methyl (methyl 4,5,7,8,9-penta-*O*-acetyl-3-deoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (**7**) as a colourless foam, 6.17 g (87% from **3**). Subsequent Zemplen de-*O*-acetylation of the peracetate **7** (5.96 g, 11.77 mmol) under standard conditions (NaOMe/MeOH) furnished the title compound **2** as a colourless foam, 2.07 g (59%).

7: mp 112–116°C (lit.¹² 115–116°C); ^1H NMR (CDCl₃) data were consistent with the literature¹²; ^{13}C NMR (CDCl₃) δ 20.6, 20.8, 21.0 (OCOCH₃ \times 5), 37.4 (C-3), 52.5, 52.7 (OCH₃, COOCH₃), 62.2 (C-9), 66.7, 67.8, 67.9, 69.3, 71.2 (C-4, C-5, C-6, C-7, C-8), 98.9 (C-2), 167.7, 169.8, 170.1, 170.6 (carbonyls); LRMS m/z : 507 (MH⁺, 2%), 474 (25), 446 (60), 414 (100); IR (ν_{max} , KBr): 1750, 1736, 1370, 1232, 1066 cm⁻¹.

2: ^1H NMR (D₂O) and IR data were consistent with the literature¹²; ^{13}C NMR (D₂O) δ 41.0 (C-3), 54.3 (OCH₃), 56.0 (COOCH₃), 65.8 (C-9), 70.7, 71.8, 72.3,



73.6, 76.7 (C-4, C-5, C-6, C-7, C-8), 101.9 (C-2), 172.7 (carbonyl); LRMS m/z : 297 (MH^+ , 3%), 265 (100), 229 (50), 169 (33), 144 (23).

Methyl (Methyl 3-Deoxy-9-*O*-*p*-toluenesulfonyl-D-glycero- α -D-galacto-2-nonulopyranosid)onate (8). To a stirred solution of **2** (427 mg, 1.44 mmol) in pyridine (9 mL) at 0°C, was added *p*-TsCl (426 mg, 2.23 mmol). After stirring at the same temperature for 2.5 h, additional *p*-TsCl (82 mg, 0.43 mmol) was added and stirring maintained for a further 20 h at 5°C. The reaction mixture was allowed to warm up to rt before MeOH (9 mL) was added. After 1 h, the volatiles were removed under reduced pressure and the residue purified by chromatography (EtOAc) which provided the 9-*O*-tosylate **8** as a colourless solid (620 mg; 96%): $[\alpha]_D -13.2^\circ$ (*c* 3.25, $CHCl_3$); 1H NMR (D_2O) δ 1.63 (1 H, dd, $J_{3ax,3eq}$ 12.3, $J_{3ax,4}$ 12.9, H-3^{ax}), 2.35 (3 H, s, $PhCH_3$), 2.52 (1 H, dd, $J_{3eq,4}$ 4.5, H-3^{eq}), 3.10 (3H, s, OCH_3), 3.40 (1 H, dd, $J_{5,4}$ 9.2, $J_{5,6}$ 9.7, H-5), 3.50 (1 H, m, H-4), 3.56 (1 H, pseudo d, H-6), 3.76 (3 H, s, $COOCH_3$), 3.91 (2 H, m, $J_{8,9'}$ 6.8, H-7, H-8), 4.16 (1 H, dd, $J_{9,9'}$ 10.4, H-9), 4.34 (1 H, pseudo d, H-9'), 7.39–7.75 (4 H, m; Ph); ^{13}C NMR (D_2O) δ 23.4 ($Ph-CH_3$), 41.2 (C-3), 54.3, 55.9 (OCH_3 , $COOCH_3$), 70.7, 71.7, 71.9, 72.2, 76.8 (C-4, C-5, C-6, C-7, C-8), 75.3 (C-9), 102.0 (C-2), 130.5, 132.9, 138.1, 149.2 (aromatic carbons), 172.5 (carbonyl); LRMS m/z : 451 (MH^+ , 3%), 418 (77), 382 (42), 351 (23), 211 (25), 185 (26), 173 (29) no base peak was observed; IR (ν_{max} , KBr): 3480, 2956, 1742, 1588, 1452, 1356, 1290, 1172, 1094, 974 cm^{-1} .

Methyl (Methyl 4,5,7,8-Tetra-*O*-acetyl-3-deoxy-9-*O*-*p*-toluenesulfonyl-D-glycero- α -D-galacto-2-nonulopyranosid)onate (9). Acetylation of **8** (30 mg, 0.07 mmol) according to the general conditions gave, after chromatography (EtOAc/Hex, 1:1), **9** as a colourless solid (39 mg; 96%): $[\alpha]_D -10.4^\circ$ (*c* 6.12, $CHCl_3$); 1H NMR ($CDCl_3$) δ 1.87 (1 H, dd, $J_{3ax,3eq}$ 13.0, $J_{3ax,4}$ 12.4, H-3^{ax}), 1.99 (6 H, s, $OAc \times 2$), 2.03, 2.09 (each 3 H, s, $OAc \times 2$), 2.44 (3 H, s, $PhCH_3$), 2.63 (1 H, dd, $J_{3eq,4}$ 4.5, H-3^{eq}), 3.26 (3H, s, OCH_3), 3.81 (3 H, s, $COOCH_3$), 4.05 (1 H, dd, $J_{9,8}$ 3.9, $J_{9,9'}$ 12.1, H-9), 4.09 (1 H, dd, $J_{6,5}$ 9.8, $J_{6,7}$ 3.0, H-6), 4.32 (1 H, dd, $J_{9,7}$ 2.2, H-9'), 4.80 (1 H, pseudo t, $J_{5,4}$ 9.5, H-5), 4.90 (1 H, m, H-4), 5.37 (2 H, m, $J_{7,8}$ 8.3, H-7, H-8), 7.33–7.77 (4 H, m, Ph); ^{13}C NMR ($CDCl_3$) δ 20.5, 20.7, 20.8, 20.9 ($OCOCH_3 \times 4$), 21.6 ($PhCH_3$), 37.3 (C-3), 52.4, 52.8 (OCH_3 , $COOCH_3$), 66.6, 67.4, 67.8, 69.3, 71.3 (C-4, C-5, C-6, C-7, C-8), 67.4 (C-9), 98.9 (C-2), 128.0, 129.8, 132.8, 144.9 (aromatic carbons), 167.6, 169.5, 170.0, 170.6 (carbonyls); LRMS m/z : 610 (MH^+ , 2%), 559 (29), 527 (100), ; IR (ν_{max} , KBr): 3508, 1748, 1598, 1444, 1368, 1218 cm^{-1} .

Anal. Calcd for $C_{26}H_{34}O_{15}S$: C, 50.48; H, 5.54. Found: C 50.49; H 5.60.

Methyl (Methyl 3,9-Dideoxy-9-iodo-D-glycero- α -D-galacto-2-nonulopyranosid)onate (10). Sodium iodide (259 mg, 1.73 mmol) was added to a solution of **8** (259 mg, 0.58 mmol) in acetone (25 mL) and the mixture heated under reflux for 2.5 days. After cooling and removal of volatiles under reduced pressure, flash chromatography (EtOAc) gave the 9-iodide **10** as an amorphous mass (255 mg;



96%): $[\alpha]_D -10.7^\circ$ (*c* 6.26, CHCl_3); $^1\text{H NMR}$ (D_2O) δ 1.78 (1 H, dd, $J_{3\text{ax},3\text{eq}}$ 12.6, $J_{3\text{ax},4}$ 12.4, H-3^{ax}), 2.66 (1 H, dd, $J_{3\text{eq},4}$ 4.6, H-3^{eq}), 3.40 (3H, s, OCH_3), 3.55 (2 H, m, H-4, H-5), 3.69 (3 H, m, H-6, H-7, H-8), 3.83 (2 H, m, H-9, H-9'), 3.92 (3 H, s, COOCH_3); $^{13}\text{C NMR}$ (D_2O) δ 15.9 (C-9), 41.0 (C-3), 54.3, 56.0 (OCH_3 , COOCH_3), 71.7, 71.8, 72.4, 73.4, 76.6 (C-4, C-5, C-6, C-7, C-8), 101.9 (C-2), 172.6 (carbonyl); LRMS *m/z*: 407 (MH^+ , 2%), 375 (100), 339 (47); IR (ν_{max} , KBr): 3448, 1734, 1632, 1438, 1290, 1202, 1070, 1036 cm^{-1} .

Methyl (Methyl 4,5,7,8-Tetra-*O*-acetyl-3,9-dideoxy-9-iodo- α -*D*-galacto-2-nonulopyranosid)onate (11). Acetylation of **10** (121 mg, 0.30 mmol) according to the general conditions gave, after chromatography (EtOAc/Hex, 1:1), **11** as a colourless solid (148 mg; 86%): $[\alpha]_D -10.5^\circ$ (*c* 7.54, CHCl_3); $^1\text{H NMR}$ (CDCl_3) δ 1.91 (1 H, dd, $J_{3\text{ax},3\text{eq}}$ 12.6, $J_{3\text{ax},4}$ 12.2, H-3^{ax}), 2.01 (6 H, s, $\text{OAc} \times 2$), 2.14, 2.19 (each 3 H, s, $\text{OAc} \times 2$), 2.66 (1 H, dd, $J_{3\text{eq},4}$ 4.1, H-3^{eq}), 3.21 (1 H, dd, $J_{9,9'}$ 11.2, $J_{9,8}$ 6.2, H-9), 3.34 (3 H, s, OCH_3), 3.58 (1 H, dd, $J_{9',8}$ 3.5, H-9'), 3.84 (3 H, s, COOCH_3), 4.18 (1 H, pseudo d, H-6), 4.86 (1 H, pseudo t, $J_{5,4}$ 9.3, H-5), 4.93 (1 H, m, H-4), 5.16 (1 H, m, $J_{8,7}$ 7.5, H-8), 5.28 (1 H, m, H-7); $^{13}\text{C NMR}$ (CDCl_3) δ 3.8 (C-9), 20.6, 20.7, 21.0 ($\text{OCOCH}_3 \times 4$), 37.3 (C-3), 52.4, 52.8 (OCH_3 , COOCH_3), 67.9, 69.2, 69.3, 69.6, 71.5 (C-4, C-5, C-6, C-7, C-8), 99.0 (C-2), 167.7, 169.8, 169.9 (carbonyls); LRMS *m/z*: 515 ($\text{MH}^+ - \text{OAc}$, 46%), 483 (100), 357 (34), 321 (22); IR (ν_{max} , KBr): 1750, 1436, 1370, 1218, 1144, 1088, 1056 cm^{-1} .

Anal. Calcd for $\text{C}_{19}\text{H}_{27}\text{O}_{12}\text{I}$: C, 39.74; H, 4.74. Found: C, 39.85; H 4.75.

Methyl (Methyl 4,5,7,8-Tetra-*O*-acetyl- 3,9-dideoxy-9-thioacetyl- α -*D*-galacto-2-nonulopyranosid)onate (12). A mixture of the 9-*O*-tosylate **8** (99 mg, 0.22 mmol), KSAc (30 mg, 0.40 mmol) and acetone (20 mL) was stirred at rt for 36 h. A further portion of KSAc (60 mg; 0.79 mmol) was added and the mixture stirred for 5 days. The mixture was filtered and the filtrate concentrated. The resulting residue was acetylated according to the general conditions. After chromatography (EtOAc/Hex, 1:1), the title compound **12** was obtained as a colourless foam (76 mg; 66%): $[\alpha]_D +8.2^\circ$ (*c* 4.13, CHCl_3); $^1\text{H NMR}$ (CDCl_3) δ 1.86 (1 H, dd, $J_{3\text{ax},3\text{eq}}$ 12.9, $J_{3\text{ax},4}$ 12.5, H-3^{ax}), 1.96, 1.97, 2.08, 2.10 (each 3 H, s, $\text{OAc} \times 4$), 2.28 (3 H, s, SCOCH_3), 2.60 (1 H, dd, $J_{3\text{eq},4}$ 4.4, H-3^{eq}), 2.93 (1 H, dd, $J_{9,9'}$ 14.6, $J_{9,8}$ 5.7, H-9), 3.29 (3H, s, OCH_3), 3.42 (1 H, dd, $J_{9',8}$ 3.6, H-9'), 3.79 (3 H, s, COOCH_3), 4.14 (1 H, dd, $J_{6,5}$ 10.0, $J_{6,7}$ 2.1, H-6), 4.82 (1 H, pseudo t, $J_{5,4}$ 9.5, H-5), 4.86 (1 H, m, H-4), 5.25 (2 H, m, $J_{7,8}$ 8.8, H-7) 5.40 (1 H, m, H-8); $^{13}\text{C NMR}$ (CDCl_3) δ 20.8, 20.9, 21.0, 21.2 ($\text{OCOCH}_3 \times 4$), 29.9 (C-9), 30.5 (SCOCH_3), 37.6 (C-3), 52.7, 52.9 (OCH_3 , COOCH_3), 68.2, 68.3, 68.4, 69.5, 71.5 (C-4, C-5, C-6, C-7, C-8), 99.1 (C-2), 167.9, 170.0, 170.1, 170.2, 170.3, 194.7 (carbonyls); LRMS *m/z*: 523 (MH^+ , 6%), 495 (31), 463 (31), 431 (100), 389 (54); IR (ν_{max} , KBr): 3668, 2964, 1754, 1698, 1436, 1370, 1220, 1108, 1088, 1054 cm^{-1} .

Anal. Calcd for $\text{C}_{21}\text{H}_{30}\text{O}_{13}\text{S}$: C, 48.27; H, 5.79. Found: C, 48.52; H 5.95.



Methyl (Methyl 9-Azido-3,9-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (13).

Procedure A. LiN₃ (0.85 g, 13.25 mmol) was added to a solution of the 9-tosylate **8** (1.99 g, 4.42 mmol) in DMF (50 mL). After stirring at 50°C for 3 days, the reaction mixture was cooled and then concentrated under reduced pressure. The resulting residue was subjected to column chromatography (CH₂Cl₂/acetone, 1:1) which furnished **13** as a colourless amorphous mass (1.30 g; 91%).

Procedure B. A solution of triphenylphosphine (207 mg, 0.79 mmol) in DMF (2 mL) was cooled to 0°C prior to the addition of DIAD (0.16 mL, 0.81 mmol). The temperature was maintained at 0°C for 15 min before azidotrimethylsilane (0.06 mL, 0.45 mmol) was added dropwise. The resulting solution was allowed to warm to rt over 2 h and stirred for 1 h. The solution was then re-cooled to 0°C and a solution of methyl (methyl 3-deoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (**2**) (117 mg, 0.40 mmol) in DMF (4 mL) added. The resulting solution was slowly warmed to rt and stirred at rt for 3 days. The residue obtained after solvent removal was purified by chromatography as described above to give **13** (69 mg; 54%): [α]_D -21.0° (*c* 3.28, CHCl₃); ¹H NMR (D₂O) δ 1.83 (1 H, dd, *J*_{3ax,3eq} 12.8, *J*_{3ax,4} 12.4, H-3^{ax}), 2.70 (1 H, dd, *J*_{3eq,4} 4.5, H-3^{eq}), 3.44 (3H, s, OCH₃), 3.59 (2 H, m, H-9, H-9'), 3.72 (2 H, m, H-4, H-5), 3.83 (1 H, m, H-7), 3.96 (4 H, m, H-6, COOCH₃), 4.10 (1 H, m, H-8); ¹³C NMR (D₂O) δ 46.2 (C-3), 59.5, 61.1 (OCH₃, COOCH₃), 71.9 (C-9), 76.4, 77.0, 77.5, 77.6, 81.8 (C-4, C-5, C-6, C-7, C-8), 107.1 (C-2), 177.8 (carbonyl); LRMS *m/z*: 322 (MH⁺, 8%), 290 (100); IR (ν _{max}, KBr): 3460, 2932, 2856, 2104, 1738, 1444, 1382, 1288, 1198, 1066, 1032 cm⁻¹.

Methyl (Methyl 4,5,7,8-Tetra-O-acetyl-9-azido-3,9-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (14). Acetylation of the azide **13** (55 mg; 0.17 mmol) according to the general conditions provided, after chromatography (EtOAc/Hex, 1:1), **14** as a colourless amorphous mass (80 mg; 95%): [α]_D -5.0° (*c* 2.09, CHCl₃); ¹H NMR (CDCl₃) δ 1.87 (1 H, dd, *J*_{3ax,3eq} 13.3, *J*_{3ax,4} 11.4, H-3^{ax}), 1.96, 1.97, 2.09, 2.15 (each 3 H, s, OAc \times 4), 2.62 (1 H, dd, *J*_{3eq,4} 4.0, H-3^{eq}), 3.24 (1 H, dd, *J*_{9,9'} 13.9, *J*_{9,8} 4.8, H-9), 3.28 (3H, s, OCH₃), 3.57 (1 H, dd, *J*_{9',8} 2.2, H-9'), 3.79 (3 H, s, COOCH₃), 4.14 (1 H, dd, *J*_{6,5} 8.8, *J*_{6,7} 1.3, H-6), 4.83 (1 H, pseudo t, *J*_{5,4} 9.7, H-5), 4.86 (1 H, m, H-4), 5.32 (2 H, m, *J*_{8,7} 7.2, H-7, H-8); ¹³C NMR (CDCl₃) δ 20.7, 20.9, 21.1 (OCOCH₃ \times 4), 37.5 (C-3), 51.0 (C-9), 52.6, 52.9 (OCH₃, COOCH₃), 67.6, 68.0, 69.2, 69.3, 71.6 (C-4, C-5, C-6, C-7, C-8), 99.1 (C-2), 167.8, 170 (carbonyls); LRMS *m/z*: 490 (MH⁺, 2%), 464 (42), 430 (43), 328 (76), 268 (100); IR (ν _{max}, KBr): 2100, 1744, 1444, 1370, 1282, 1220, 1152, 1114, 1088, 1054, 1002 cm⁻¹.

Anal. Calcd for C₁₉H₂₇O₁₂N₃: C, 46.63; H, 5.56; N, 8.59. Found: C, 46.87; H 6.00; N, 8.21.

Methyl (Methyl 9-Amino-3,9-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (15). Treatment of a mixture of the 9-azide **13** (1.14 g, 3.53 mmol), glacial acetic acid (6 drops) and MeOH (40 mL) under hydrogenolysis



conditions (50 psi, 10% Pd/C, 3.5 days) gave, after chromatography (EtOAc/MeOH/H₂O, 25:15:1), the 9-amine **13** as a colourless amorphous mass (1.04 g; 99%): $[\alpha]_D -20.8^\circ$ (*c* 5.72, MeOH); ¹H NMR (D₂O) 1.65 (1 H, dd, $J_{3ax,3eq}$ 12.8, $J_{3ax,4}$ 12.4, H-3^{ax}), 2.52 (1 H, dd, $J_{3eq,4}$ 4.6, H-3^{eq}), 2.97 (1 H, dd, $J_{9,9'}$ 13.2, $J_{9,8}$ 9.1, H-9), 3.25 (3 H, s, OCH₃), 3.33 (1 H, dd, $J_{9',8}$ 3.1, H-9'), 3.41 (1 H, pseudo t, $J_{5,4}$ 9.5, $J_{5,6}$ 9.5, H-5), 3.52 (2 H, m, $J_{7,8}$ 6.7, H-7, H-8), 3.65 (1 H, pseudo d, H-6), 3.77 (3 H, s, COOCH₃), 3.94 (1 H, m, H-4); ¹³C NMR (D₂O) δ 41.0 (C-3), 45.2 (C-9), 54.4, 56.0 (OCH₃, COOCH₃), 70.9, 71.7, 72.2, 72.5, 76.7 (C-4, C-5, C-6, C-7, C-8), 102.0 (C-2), 175.2 (carbonyl); LRMS *m/z*: 296 (MH⁺, 100%), 264 (42), 185 (35); IR (ν_{max} , KBr): 3368, 2948, 1740, 1570, 1412, 1342, 1290, 1198, 1068, 1034, 652 cm⁻¹. HRMS: Calcd for C₁₁H₂₁NO₈: [M⁺ + 1], 296.1346. Found: 296.1342.

Methyl (Methyl 9-Acetamido-4,5,7,8-tetra-O-acetyl-3,9-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (16). Acetylation of the amine **15** (31 mg, 0.11 mmol) according to the general conditions gave, after chromatography (EtOAc), the 9-acetamide **16** as a colourless syrup (36 mg; 68%): $[\alpha]_D -17.7^\circ$ (*c* 3.41, CHCl₃); ¹H NMR (CDCl₃) δ 1.91 (1 H, dd, $J_{3ax,3eq}$ 12.9, $J_{3ax,4}$ 11.9, H-3^{ax}), 1.98, 2.01, 2.02, 2.15, 2.17 (each 3 H, s, OAc \times 4, NHCOCH₃), 2.67 (1 H, dd, $J_{3eq,4}$ 4.4, H-3^{eq}), 2.99 (1 H, dd, $J_{9,8}$ 4.6, $J_{9,9'}$ 9.1, $J_{9,NH}$ 6.0, H-9), 3.33 (3 H, s, OCH₃), 3.82 (3 H, s, COOCH₃), 3.94 (1 H, ddd, $J_{9',8}$ 2.9, $J_{9',NH}$ 7.4, H-9'), 4.16 (1 H, dd, $J_{6,5}$ 9.9, $J_{6,7}$ 2.1, H-6), 4.93 (1 H, m, H-4), 4.98 (1 H, pseudo t, $J_{5,4}$ 10.5, H-5), 5.15 (1 H, dd, $J_{7,8}$ 9.5, H-7), 5.25 (1 H, m, H-8), 5.95 (1 H, br t, NHCOCH₃); ¹³C NMR (CDCl₃) δ 20.6, 20.7, 21.0 (OCOCH₃ \times 4), 23.2 (NHCOCH₃), 37.4 (C-3), 38.5 (C-9), 52.4, 52.7 (OCH₃, COOCH₃), 67.2, 68.0, 68.3, 69.2, 70.9 (C-4, C-5, C-6, C-7, C-8), 98.8 (C-2), 169.8, 170.2, 171.2 (carbonyls); LRMS *m/z*: 506 (MH⁺, 65%), 446 (37), 414 (100), 372 (62), 312 (31); IR (ν_{max} , KBr): 1752, 1678, 1438, 1370, 1220, 1112, 1088, 1052 cm⁻¹.

Anal. Calcd for C₂₁H₃₁NO₁₃.CHCl₃: C, 42.32; H, 5.13; N, 2.25. Found: C, 42.32; H, 5.17; N, 2.20.

Methyl (Methyl 9-Acetamido-3,9-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (17). Treatment of a solution of peracetylated 9-acetamide **16** (125 mg; 0.370 mmol) in MeOH under standard Zemplen de-O-acetylation conditions (NaOMe, 30 min) followed by conventional workup gave the title compound **17** as a colourless amorphous mass (60 mg; 72%): $[\alpha]_D -30.6^\circ$ (*c* 6.03, MeOH); ¹H NMR (D₂O) 1.65 (1 H, dd, $J_{3ax,3eq}$ 12.8, $J_{3ax,4}$ 12.4, H-3^{ax}), 1.94 (3 H, s, NHCOCH₃), 2.52 (1 H, dd, $J_{3eq,4}$ 4.6, H-3^{eq}), 3.24 (1 H, dd, $J_{9,9'}$ 14.3, $J_{9,8}$ 7.3, H-9), 3.26 (3 H, s, OCH₃), 3.44 (1 H, dd, $J_{5,4}$ 9.3, $J_{5,6}$ 9.6, H-5), 3.55 (2 H, m, $J_{6,7}$ 0.8, $J_{9',8}$ 2.8, H-6, H-9'), 3.65 (1 H, dd, $J_{7,8}$ 6.0, H-7), 3.68 (1 H, m, H-8), 3.78 (3 H, s, COOCH₃), 3.83 (1 H, m, H-4); ¹³C NMR (D₂O) δ 24.6 (NHCOCH₃), 41.0 (C-3), 45.3 (C-9), 54.4, 56.0 (OCH₃, COOCH₃), 71.7, 71.8, 72.1, 72.3, 76.7 (C-4, C-5, C-6, C-7, C-8), 102.0 (C-2), 171.3 (carbonyl); LRMS *m/z*: 338 (MH⁺, 96%), 306 (100); IR (ν_{max} , KBr): 3348, 2948, 1738, 1638, 1562, 1438, 1374, 1292, 1198, 1072, 984, 880, 782, 650, 454 cm⁻¹. HRMS: Calcd for C₁₃H₂₃NO₉: [M⁺ + 1], 338.1451. Found: 338.1443.



Methyl (Methyl 9-Benzamido-3,9-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (18). A solution of the 9-amine **15** (91 mg; 0.308 mmol) and freshly distilled Et₃N (1.2 mL) in MeOH (10 mL) was cooled to -70°C prior to the addition of benzoyl chloride (0.5 mL). After 35 min, the solution was warmed to rt and concentrated. Chromatography (EtOAc) gave the title compound **18** (84 mg; 68%): $[\alpha]_{\text{D}} -10.4^{\circ}$ (c 7.08, MeOH); ^1H NMR (D₂O) 1.88 (1 H, dd, $J_{3\text{ax},3\text{eq}}$ 12.9, $J_{3\text{ax},4}$ 11.9, H-3^{ax}), 2.74 (1 H, dd, $J_{3\text{eq},4}$ 3.5, H-3^{eq}), 2.97 (1 H, dd, $J_{9,8}$ 9.1, $J_{9,9'}$ 13.2, H-9), 3.48 (3 H, s, OCH₃), 3.72 (4 H, m, H-5, H-6, H-9, H-9'), 3.94 (2 H, m, H-7, H-8), 3.99 (3 H, s, COOCH₃), 4.17 (1 H, m, H-4), 7.66–7.73 (5 H, m, Ph); ^{13}C NMR (D₂O) δ 41.4 (C-3), 46.2 (C-9), 54.7, 56.3 (OCH₃, COOCH₃), 72.2, 72.3, 72.6, 72.7, 77.1 (C-4, C-5, C-6, C-7, C-8), 102.3 (C-2), 130.1, 131.8, 135.1, 136.6 (aromatic carbons), 173.0 (carbonyl); LRMS m/z : 400 (MH⁺, 11%), 367 (79) no base peak was observed; IR (ν_{max} , KBr): 3420, 2948, 1732, 1632, 1576, 1544, 1480, 1450, 1290, 1196, 1070, 984, 780, 710, 656 cm⁻¹. HRMS: Calcd for C₁₈H₂₅NO₉: [M⁺ + 1], 400.1608. Found: 400.1613.

Methyl (Methyl 4,5,7,8-Tetra-O-acetyl-9-benzamido-3,9-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (19). According to the general conditions, acetylation of **18** (84 mg, 0.21 mmol) gave, after chromatography (EtOAc), the title compound **19** as a colourless solid (71 mg; 92%): $[\alpha]_{\text{D}} +4.2^{\circ}$ (c 4.35, CHCl₃); ^1H NMR (CDCl₃) δ 1.91 (1 H, dd, $J_{3\text{ax},3\text{eq}}$ 12.9, $J_{3\text{ax},4}$ 12.1, H-3^{ax}), 2.01 (6 H, s, OAc \times 2), 2.01, 2.15 (each 3 H, s, OAc \times 2), 2.69 (1 H, dd, $J_{3\text{eq},4}$ 4.6, H-3^{eq}), 3.12 (1 H, dd, $J_{9,8}$ 8.7, $J_{9,9'}$ 15.0, $J_{9,\text{NH}}$ 4.5, H-9), 3.33 (3 H, s, OCH₃), 3.81 (3 H, s, COOCH₃), 4.17 (1 H, dd, $J_{6,5}$ 9.7, $J_{6,7}$ 2.2, H-6), 4.24 (1 H, ddd, $J_{9',8}$ 2.9, $J_{9',\text{NH}}$ 7.5, H-9'), 4.92 (1 H, m, H-4), 4.98 (1 H, pseudo t, $J_{5,4}$ 9.6, H-5), 5.22 (1 H, dd, $J_{7,8}$ 9.7, H-7), 5.36 (1 H, m, H-8), 6.86 (1 H, br dd, NH), 7.46–7.79 (5 H, m, Ph); ^{13}C NMR (CDCl₃) δ 20.8, 20.9, 21.0, 21.3 (OCOCH₃ \times 4), 37.7 (C-3), 39.2 (C-9), 52.6, 52.9 (OCH₃, COOCH₃), 67.8, 68.3, 68.6, 69.5, 71.2 (C-4, C-5, C-6, C-7, C-8), 99.1 (C-2), 127.1, 128.7, 131.6, 134.7 (aromatic carbons), 167.6, 167.8, 170.1, 170.7, 171.8 (carbonyls); LRMS m/z : 569 (MH⁺, 20%), 507 (48), 475 (100); IR (ν_{max} , KBr): 1756, 1636, 1536, 1436, 1372, 1246, 1116, 1054, 990, 702 cm⁻¹.

Anal. Calcd for C₂₆H₃₃NO₁₃·1.5 H₂O: C, 52.51; H, 6.11; N, 2.35. Found: C, 52.38; H, 5.85; N, 2.05.

Methyl (Methyl 3,9-Dideoxy-D-glycero- α -D-galacto-2-nonulopyranosid)onate (20). A solution of the 9-iodide **10** (23 mg, 0.058 mmol) and glacial acetic acid (2 drops) in MeOH (2 mL) was subjected to hydrogenolysis conditions (50 psi H₂, 10% Pd/C) until complete disappearance of starting material (as monitored by TLC; EtOAc/MeOH, 10:1). The solids were then filtered off and filtrate concentrated. The resulting residue was chromatographed (EtOAc/MeOH, 20:1) which gave the title compound **20** (16 mg; 99%): $[\alpha]_{\text{D}} -39.8^{\circ}$ (c 2.82, CHCl₃); ^1H NMR (D₂O) δ 1.25 (3 H, d, $J_{9,8}$ 6.3, H-9 \times 3), 1.69 (1 H, dd, $J_{3\text{ax},3\text{eq}}$ 12.9, $J_{3\text{ax},4}$ 12.4, H-3^{ax}), 2.57 (1 H, dd, $J_{3\text{eq},4}$ 4.6, H-3^{eq}), 3.30 (3H, s, OCH₃), 3.50 (4 H, m, H-5, H-6, H-7, H-8), 3.82 (3 H, s, COOCH₃), 3.92 (1 H, m, H-4); ^{13}C NMR (D₂O) δ 25.0 (C-9), 44.4 (C-3), 57.7, 59.4 (OCH₃, COOCH₃), 73.4, 75.3, 75.9, 78.1, 80.2



(C-4, C-5, C-6, C-7, C-8), 105.3 (C-2), 176.1 (carbonyl); LRMS m/z : 281 (MH^+ , 4%), 249 (100); IR (ν_{max} , KBr): 3508, 2944, 1736, 1644, 1448, 1290, 1200, 1078 cm^{-1} .

Methyl (Methyl 4,5,7,8-Tetra-*O*-acetyl-3,9-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate (21). Acetylation of **20** (47 mg, 0.17 mmol) according to the general conditions gave, after chromatography (EtOAc/hexane, 1:1) **21** as a colourless solid (64 mg; 86%): $[\alpha]_D -17.2^\circ$ (c 5.42, $CHCl_3$); 1H NMR ($CDCl_3$) δ 1.20 (3 H, d, $J_{9,8}$ 6.2, H-9 \times 3), 1.88 (1 H, dd, $J_{3ax,3eq}$ 12.6, $J_{3ax,4}$ 11.9, H-3^{ax}), 1.99 (6 H, s, OAc \times 2), 2.10, 2.11 (each 3 H, s, OAc \times 2), 2.65 (1 H, dd, $J_{3eq,4}$ 3.6, H-3^{eq}), 3.31 (3 H, s, OCH_3), 3.81 (3 H, s, $COOCH_3$), 4.15 (1 H, dd, $J_{6,5}$ 8.2, $J_{6,7}$ 1.7, H-6), 4.91 (2 H, m, $J_{4,5}$ 8.3, H-4, H-5), 5.14 (1 H, dd, $J_{7,8}$ 8.7, H-7), 5.27 (1 H, m, H-8); ^{13}C NMR ($CDCl_3$) δ 16.6 (C-9), 20.6, 20.7, 21.4 ($OCOCH_3 \times$ 4), 37.4 (C-3), 52.3, 52.6 (OCH_3 , $COOCH_3$), 66.8, 68.1, 69.3, 70.2, 71.1 (C-4, C-5, C-6, C-7, C-8), 98.8 (C-2), 170.0 (carbonyls); LRMS m/z : 449 (MH^+ , 4%), 389 (37), 357 (100); IR (ν_{max} , KBr): 1750, 1370, 1236, 1092 cm^{-1} .

Anal. Calcd for $C_{19}H_{28}O_{12}$: C, 50.89; H, 6.29. Found: C, 50.70; H, 6.30.

ACKNOWLEDGMENTS

This work was supported by an Australian Postgraduate Award to AKN and by the Australian Research Council.

REFERENCES

1. Rosenberg, A., Ed. *Biology of the Sialic Acids*, Plenum Press: New York, 1995.
2. Nadano, D.; Iwasaki, M.; Endo, S.; Kitajima, K.; Inoue, S.; Inoue, Y. A naturally occurring deaminated neuraminic acid, 3-deoxy-D-glycero-D-galacto-nonulosonic acid (KDN). Its unique occurrence at the nonreducing ends of oligosialyl chains in polysialoglycoprotein of rainbow trout eggs. *J. Biol. Chem.* **1986**, *261*(25), 11550–11557.
3. Schreiner, E; Zbiral E. Structural variations of *N*-acetylneuraminic acid. 16. A convenient approach to 3-deoxy-D-glycero-D-galacto-nonulosonic acid (KDN), 5-azido-5-deoxy-KDN and 5-deoxy-KDN, and their 4-methylumbelliferyl 2α-glycosides. *Liebigs Ann. Chem.* **1990**, 581–586, and references cited therein.
4. Knirel, Y.A.; Shashkov, N.A.; Kochetkov, N.K.; Mamontova, V.A.; Soloveva, T.F. Structure of the capsular polysaccharide of *Klebsiella ozaenae* serotype K4 containing 3-deoxy-D-glycero-D-galacto-nonulosonic acid. *Carbohydr. Res.*, **1989**, *188*, 145–155.
5. Strecker, G.; Wieruszski, J.M.; Michalski, J.C.; Alonso, C.; Leroy, Y.; Boilly, B.; Montreuil, J. Primary structure of neutral and acidic oligosaccharide-alditols derived from the jelly coat of the Mexican axolotl. Occurrence of oligosaccharides with fucosyl(α1→3)fucosyl(α1→4)-3-deoxy-D-glycero-D-galacto-nonulosonic acid and galactosyl(α1→4)[fucosyl(α1→2)]galactosyl(β1→4)-*N*-acetylglucosamine sequences. *Eur. J. Biochem.*, **1992**, *207*(3), 995–1002.



6. Ziak, M.; Qu, B.; Zuo, X.; Zuber, C.; Kanamori, A.; Kitajima, K.; Inoue, S.; Inoue, Y.; Roth, J. Occurrence of poly(α 2,8-deaminoneuraminic acid) in mammalian tissues: Widespread and developmentally regulated but highly selective expression on glycoproteins. *Proc. Natl. Acad. Sci. USA* **1996**, *93*(7), 2759–2763.
7. Li, Y.T.; Yuziuk, J.A.; Li, S.C.; Nematalla, A.; Hasegawa, A.; Kimura, M.; Nakagawa, H. A novel sialidase capable of cleaving 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN). *Arch. Biochem. Biophys.*, **1994**, *310*, 243–246.
8. Nishino, S.; Kuroyanagi, H.; Terada, T.; Inoue, S.; Inoue, Y.; Troy, F.A. 2nd; Kitajima, K. Induction, localization, and purification of a novel sialidase, deaminoneuraminidase (KDNase), from *Sphingobacterium multivorum*. *J. Biol. Chem.*, **1996**, *271*(6), 2909–2913.
9. See for example: Terada, T.; Kitajima, K.; Inoue, S.; Wilson, J.C.; Norton, A.K.; Kong, D.C.M.; Thomson, R.J.; von Itzstein, M.; Inoue, Y. Catalysis by a new sialidase, deaminoneuraminic acid residue-cleaving enzyme (KDNase Sm), initially forms a less stable α -anomer of 3-deoxy-D-glycero-D-galacto-nonulosonic acid and is strongly inhibited by the transition state analogue, 2-deoxy-2,3-didehydro-D-glycero-D-galacto-2-nonulopyranosonic acid, but not by 2-deoxy-2,3-didehydro-N-acetylneuraminic acid. *J. Biol. Chem.*, **1997**, *272*(9), 5452–5456.
10. von Itzstein, M.; Thomson, R.J. The synthesis of novel sialic acids as biological probes. In *Topics in Current Chemistry*; Driguez, H.; Thiem, J., Eds.; Springer-Verlag: Berlin, 1997; Vol 186, 119–170.
11. von Itzstein, M.; Thomson, R.J. Sialic acids and sialic acid-recognising proteins: drug discovery targets and potential glycopharmaeuticals. *Curr. Med. Chem.*, **1997**, *4*, 185–210.
12. Nakamura, M.; Takayanagi, H.; Furuhashi, K.; Ogura, H. Synthesis and characterization of furanose and pyranose derivatives of 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN). *Chem. Pharm. Bull.*, **1992**, *40*(4), 879–885.
13. Kononov, L.O.; Magnusson, G. Synthesis of methyl and allyl α -glycosides of N-acetylneuraminic acid in the absence of added promoter. *Acta Chem. Scand.*, **1998**, *48*(1), 141–144.
14. Fitz, W.; Rosenthal, P.B.; Wong, C-H. Synthesis and inhibitory properties of a thiomethylmercuric sialic acid with application to the x-ray structure determination of 9-O-acetylsialic acid esterase from Influenza C virus. *Bioorg. Med. Chem.*, **1996**, *4*(8), 1349–1353.
15. Akai, S.; Nakagawa, T.; Kajihara, Y.; Sato, K. Selective protecting method for the individual hydroxyl groups of KDN. *J. Carbohydr. Chem.*, **1999**, *18*(6), 639–654.
16. Silverstein, R.M.; Bassler, G.C.; Morrill, T.C., Eds. *Spectrometric Identification of Organic Compounds*, 4th Ed, Wiley: New York, 1981.
17. Augé, C.; Gautheron, C.; David, S.; Malleron, A.; Cavayé, B.; Bouxom, B. Sialyl aldolase in organic synthesis: from the trout egg acid, 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN), to branched-chain higher ketoses as possible new chiroins. *Tetrahedron*, **1990**, *46*(1), 201–214.
18. Nakamura, M.; Furuhashi, K.; Yamasaki, T.; Ogura, H. Studies on sialic acids. XXV. Synthesis of the α - and β -N-glycosides of 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN). *Chem. Pharm. Bull.*, **1991**, *39*, 3140–3144.

Received October 10, 2000

Accepted November 25, 2000



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081CAR100103960>